Ronald Kern's Article Examines Unresolved Issues of BPCIA Interpretation

Articles / March 16, 2016

Associate Ronald Kern authored an article for the March 14, 2016, issue of Intellectual Property Litigation, a publication of the American Bar Association (ABA) Litigation Section. The article, “Unanswered Issues in the Federal Circuit’s Amgen v. Sandoz Decision,” analyzes several issues that remain unresolved following the Federal Circuit’s interpretation of the Biologics Price Competition and Innovation Act (BPCIA). These issues include, Kern notes, the meaning of “licensed” as used in the BPCIA and the right to seek relief on patents having process vs. composition claims, among others.

Read the article.

Related Services